Zobrazeno 1 - 10
of 23 592
pro vyhledávání: ''
Autor:
Garth W. Strohbehn, Robert Holleman, Jennifer Burns, Mandi L. Klamerus, Michael J. Kelley, Eve A. Kerr, Nithya Ramnath, Timothy P. Hofer
Publikováno v:
JAMA oncology. 8(11)
ImportanceExtended-interval dosing of pembrolizumab (400 mg every 6 weeks) was approved by US Food and Drug Administration (FDA) in April 2020 as an alternative to standard-interval dosing (200 mg every 3 weeks). Extended-interval dosing may enhance
Autor:
Andrea De Giglio, Valeria Grandinetti, Marta Aprile, Greta Borelli, Anita Campus, Anna Laura Croci Chiocchini, Marco Busutti, Gisella Vischini, Alessandro Di Federico, Francesca Sperandi, Barbara Melotti, Andrea Ardizzoni, Gaetano La Manna, Francesco Gelsomino
Publikováno v:
Lung Cancer. 174:91-96
The combination of immune-checkpoint inhibitors (ICI) and platinum-pemetrexed chemotherapy (CT) in first-line setting improved survival outcomes of advanced non-small cell lung cancer (NSCLC) patients. Among the various adverse events, renal toxicity
Autor:
Keita, Kouzu, Hironori, Tsujimoto, Naoyuki, Uehata, Yusuke, Ishibashi, Yoji, Kishi, Hideki, Ueno
Publikováno v:
Anticancer Research. 42:5999-6006
This study aimed to evaluate the prognostic value of modified geriatric nutritional risk index (mGNRI) in patients with unresectable/recurrent esophageal cancer (EC).We included 143 patients aged65 years with unresectable/recurrent EC. The mGNRI was
Autor:
Jun Ho, Yi, Seok Jin, Kim, Jeong-Ok, Lee, Gyeong-Won, Lee, Jae-Yong, Kwak, Hyeon-Seok, Eom, Jae-Cheol, Jo, Yoon Seok, Choi, Sung Yong, Oh, Won Seog, Kim
Publikováno v:
Anticancer Research. 42:6083-6089
The combination of bendamustine and rituximab (BR) is highly effective in both treatment-naïve and relapsed or refractory mantle cell lymphoma (MCL). Due to the rarity of MCL and limited accessibility of BR, clinical outcome from BR in the routine c
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:835-840
Gemcitabine-based regimens are effective salvage therapy for RR lymphoma patients eligible for ASCT, but there is limited data in transplant-ineligible (TIE) patients. Here, we present a retrospective analysis on the outcome of TIE adult patients wit
Autor:
Cansu, Delikanli, Stefan, Janssen, Dirk, Keil, Søren, Tvilsted, Steven E, Schild, Dirk, Rades
Publikováno v:
Anticancer Research. 42:5561-5566
Many cancer patients receive radiotherapy, which may cause distress. This pilot study evaluated distress levels before and after radiotherapy to contribute to the design of a prospective trial.Two-hundred patients completed distress thermometers befo
Autor:
Lalit Kumar, Mohammad Mir Hussain, Rajegowda Chethan, Ranjit Kumar Sahoo, Prabhat S. Malik, Om Dutt Sharma, Anisha Mathew, Ankit Jha, Ritu Gupta, Atul Sharma, Ahitagni Biswas, Rakesh Kumar, Sanjay Thulkar, Soumyaranjan Malik, Ashish Dutt
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:e826-e835
Autologous stem cell transplant (ASCT) is a standard therapy for transplant eligible patients of multiple myeloma (MM). To evaluate impact of time to transplant on subsequent outcomes, we analyzed data on consecutive MM patients who received novel ag
Autor:
Takahiro Fukushima, Yoshitaka Oyamada, Shinnosuke Ikemura, Shigenari Nukaga, Takashi Inoue, Daisuke Arai, Keiko Ohgino, Aoi Kuroda, Kota Ishioka, Fumio Sakamaki, Yusuke Suzuki, Hideki Terai, Hiroyuki Yasuda, Ichiro Kawada, Koichi Fukunaga, Kenzo Soejima
Publikováno v:
Clinical Lung Cancer. 23:532-541
The optimal treatment for advanced non-small cell lung cancer (NSCLC) in very elderly patients is unclear. We aimed to evaluate their treatment in real-world clinical practice and identify suitable therapy that can improve their prognosis.The medical
Autor:
Taro Yoneda, Takashi Sone, Hayato Koba, Kazuhiko Shibata, Junya Suzuki, Mayuko Tani, Masaru Nishitsuji, Koichi Nishi, Takafumi Kobayashi, Hiroki Shirasaki, Tomoyuki Araya, Toshiyuki Kita, Kazumasa Kase, Kenta Yamamura, Nanao Terada, Shingo Nishikawa, Yuichi Tambo, Hideharu Kimura, Kazuo Kasahara
Publikováno v:
Clinical Lung Cancer. 23:467-476
Immune checkpoint inhibitor (ICI) monotherapy is more effective than cytotoxic chemotherapy in improving overall survival (OS) among patients with advanced-stage non-small cell lung cancer (NSCLC). Recently, chemotherapy combined with ICI has been fo
Publikováno v:
Anticancer Research. 42:4173-4178
Standard treatment options for primary central nervous system lymphoma (PCNSL) include high-dose methotrexate (HD-MTX)-based drug therapy and whole-brain radiation therapy. However, there are many cases in which these standard treatment options are n